Dyno Therapeutics

Yvette Leung, Vice President, Head of Corporate Development

April 13 | 2:15pm | Dark Horse Consulting Ballroom 

Watertown, MA


Dyno Therapeutics is a pioneer in applying artificial intelligence (AI) and quantitative in vivo experiments to gene therapy. The company’s proprietary CapsidMap™ platform rapidly discovers and systematically optimizes Adeno-Associated Virus (AAV) capsid vectors that significantly outperform current approaches for in vivo gene delivery, thereby expanding the range of diseases treatable with gene therapies. Dyno was founded in 2018 by experienced biotech entrepreneurs and leading scientists in the fields of gene therapy and machine learning.


By using this website you agree to accept our Privacy Policy and Terms & Conditions